The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II trial of cyclophosphamide, carfilzomib, thalidomide, and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma.
Joseph Mikhael
Research Funding - Onyx
Craig B. Reeder
No relevant relationships to disclose
Edward N. Libby
No relevant relationships to disclose
Luciano Costa
No relevant relationships to disclose
Angela Mayo
No relevant relationships to disclose
P. Leif Bergsagel
No relevant relationships to disclose
Francis Buadi
No relevant relationships to disclose
Nicholas Pirooz
No relevant relationships to disclose
Jade Marie Lubben
No relevant relationships to disclose
Amylou C. Dueck
No relevant relationships to disclose
A. Keith Stewart
Honoraria - Celgene; Onyx
Research Funding - Onyx